These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

439 related items for PubMed ID: 31857776

  • 21. Bismuth-based first-line therapy for Helicobacter pylori eradication in type 2 diabetes mellitus patients.
    Demir M, Göktürk S, Oztürk NA, Serin E, Yilmaz U.
    Digestion; 2010; 82(1):47-53. PubMed ID: 20410684
    [Abstract] [Full Text] [Related]

  • 22. [Cuadruple concomitant non-bismuth therapy vs. classical triple therapy as first line therapy for Helicobacter pylori infection].
    Campillo A, Ostiz M, Amorena E, Kutz M, La Iglesia M.
    Med Clin (Barc); 2016 Sep 02; 147(5):199-201. PubMed ID: 27374029
    [Abstract] [Full Text] [Related]

  • 23. 14-day tailored PCR-guided triple therapy versus 14-day non-Bismuth concomitant quadruple therapy for Helicobacter pylori eradication: A multicenter, open-label randomized noninferiority controlled trial.
    Amiot A, Hacoon J, Heluwaert F, Mion F, Lamarque D, Moussata D, Mimouni M, Delchier JC, Durand-Zaleski I, Audureau E, Bastuji-Garin S, HEPYSE Study Group.
    Helicobacter; 2024 Sep 02; 29(2):e13076. PubMed ID: 38680067
    [Abstract] [Full Text] [Related]

  • 24. Rescue Therapy for Helicobacter pylori Eradication: A Randomized Non-Inferiority Trial of Amoxicillin or Tetracycline in Bismuth Quadruple Therapy.
    Chen Q, Zhang W, Fu Q, Liang X, Liu W, Xiao S, Lu H.
    Am J Gastroenterol; 2016 Dec 02; 111(12):1736-1742. PubMed ID: 27670603
    [Abstract] [Full Text] [Related]

  • 25. Types of 23S Ribosomal RNA Point Mutations and Therapeutic Outcomes for Helicobacter pylori.
    Kim SY, Park JM, Lim CH, Lee HA, Shin GY, Choe Y, Cho YK, Choi MG.
    Gut Liver; 2021 Jul 15; 15(4):528-536. PubMed ID: 33376228
    [Abstract] [Full Text] [Related]

  • 26. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability.
    Luther J, Higgins PD, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD.
    Am J Gastroenterol; 2010 Jan 15; 105(1):65-73. PubMed ID: 19755966
    [Abstract] [Full Text] [Related]

  • 27. Comparative study of Helicobacter pylori eradication rates of concomitant therapy vs modified quadruple therapy comprising proton-pump inhibitor, bismuth, amoxicillin, and metronidazole in Korea.
    Choe JW, Jung SW, Kim SY, Hyun JJ, Jung YK, Koo JS, Yim HJ, Lee SW.
    Helicobacter; 2018 Apr 15; 23(2):e12466. PubMed ID: 29369454
    [Abstract] [Full Text] [Related]

  • 28. [Ten-day Sequential Therapy versus Bismuth Based Quadruple Therapy as Second Line Treatment for Helicobacter pylori Infection].
    Kim SB, Lee SH, Kim KO, Jang BI, Kim TN.
    Korean J Gastroenterol; 2015 Nov 15; 66(5):261-7. PubMed ID: 26586348
    [Abstract] [Full Text] [Related]

  • 29. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments.
    Gisbert JP, Romano M, Gravina AG, Solís-Muñoz P, Bermejo F, Molina-Infante J, Castro-Fernández M, Ortuño J, Lucendo AJ, Herranz M, Modolell I, Del Castillo F, Gómez J, Barrio J, Velayos B, Gómez B, Domínguez JL, Miranda A, Martorano M, Algaba A, Pabón M, Angueira T, Fernández-Salazar L, Federico A, Marín AC, McNicholl AG.
    Aliment Pharmacol Ther; 2015 Apr 15; 41(8):768-75. PubMed ID: 25703120
    [Abstract] [Full Text] [Related]

  • 30. Efficacy of second-line regimens for Helicobacter pylori eradication treatment: a systemic review and network meta-analysis.
    Chang YL, Tung YC, Tu YK, Yeh HZ, Yang JC, Hsu PI, Kim SE, Wu MF, Liou WS, Shiu SI.
    BMJ Open Gastroenterol; 2020 Sep 15; 7(1):. PubMed ID: 32883715
    [Abstract] [Full Text] [Related]

  • 31. Bismuth-based therapies for the first step eradication of Helicobacter pylori.
    Sezgin O, Altintaş E, Uçbilek E, Tataroğlu C.
    Turk J Gastroenterol; 2006 Jun 15; 17(2):90-3. PubMed ID: 16830288
    [Abstract] [Full Text] [Related]

  • 32. Comparison of tailored Helicobacter pylori eradication versus modified bismuth quadruple therapy in Korea: a randomized controlled trial.
    Cho JH, Jin SY, Park S.
    Expert Rev Anti Infect Ther; 2022 Jun 15; 20(6):923-929. PubMed ID: 34883037
    [Abstract] [Full Text] [Related]

  • 33. Effective Eradication Regimen and Duration According to the Clarithromycin Susceptibility of Helicobacter pylori Determined Using Dual Priming Oligonucleotide-Based Multiplex Polymerase Chain Reaction.
    Na SY, Kim BW, Kim MJ, Choe Y, Kim JS.
    Gut Liver; 2023 Sep 15; 17(5):722-730. PubMed ID: 36168964
    [Abstract] [Full Text] [Related]

  • 34. Modified quadruple therapy versus bismuth-containing quadruple therapy in first-line treatment of Helicobacter pylori infection in Korea; rationale and design of an open-label, multicenter, randomized controlled trial.
    Lim H, Bang CS, Shin WG, Choi JH, Soh JS, Kang HS, Yang YJ, Hong JT, Shin SP, Suk KT, Lee JJ, Baik GH, Kim DJ.
    Medicine (Baltimore); 2018 Nov 15; 97(46):e13245. PubMed ID: 30431605
    [Abstract] [Full Text] [Related]

  • 35. The efficacy of two-week quadruple first-line therapy with bismuth, lansoprazole, amoxicillin, clarithromycin on Helicobacter pylori eradication: a prospective study.
    Ergül B, Doğan Z, Sarikaya M, Filik L.
    Helicobacter; 2013 Dec 15; 18(6):454-8. PubMed ID: 24011287
    [Abstract] [Full Text] [Related]

  • 36. Comparison of Helicobacter pylori eradication rates between 7 and 14 days of tailored therapy according to clarithromycin resistance test: A randomized, multicenter, non-inferiority study.
    Jung K, Jee SR, Lee MW, Koh M, Kim SJ, Lee J, Park MI.
    Helicobacter; 2024 Dec 15; 29(3):e13084. PubMed ID: 38717034
    [Abstract] [Full Text] [Related]

  • 37. Efficacy comparison of 7- and 14-day P-CAB based bismuth-containing quadruple regimen with PPI based bismuth-containing quadruple regimen for Helicobacter pylori infection: rationale and design of an open-label, multicenter, randomized controlled trial.
    Oh CK, Lim H, Seo SI, Lee SP, Bang CS, Shin WG, Kim JB, Jang HJ, Baik GH.
    BMC Gastroenterol; 2023 Dec 21; 23(1):453. PubMed ID: 38129806
    [Abstract] [Full Text] [Related]

  • 38. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy.
    Zhang W, Chen Q, Liang X, Liu W, Xiao S, Graham DY, Lu H.
    Gut; 2015 Nov 21; 64(11):1715-20. PubMed ID: 26338726
    [Abstract] [Full Text] [Related]

  • 39. [Clarithromycin-resistant Helicobacter pylori associated with 23S rRNA point mutations in Jeju Island].
    Kim T, Song HJ, Shin SY, Kim JH, Na SY, Boo SJ, Choi EK, Cho YK, Kim HU, Song BC.
    Korean J Gastroenterol; 2013 May 21; 61(5):252-8. PubMed ID: 23756666
    [Abstract] [Full Text] [Related]

  • 40. Tailored Helicobacter pylori eradication based on prior intake of macrolide antibiotics allows the use of triple therapy with optimal results in an area with high clarithromycin resistance.
    Valle Muñoz J, Muñoz Gómez P, Sierra Bernal C, de Andrés E, Gómez Hernando C, Gómez Rodríguez R.
    Rev Esp Enferm Dig; 2019 Sep 21; 111(9):655-661. PubMed ID: 31345044
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.